The priority objective of mutual recognition agreements is to reduce technical barriers to trade (TT). The World Trade Organization (WTO) agreement on technical barriers to trade „urges members to engage, at the request of other members, in negotiations to conclude mutual recognition agreements resulting from the results of their respective compliance assessment procedures“ so that the results are „mutually satisfactory“ in terms of their ability to facilitate trade in the products concerned. An MRA is an agreement between two or more countries to recognize a particular procedure or procedure from the other country, and this is the first step towards greater use of the expertise and resources of the inspection of veterinary drugs from the other country. The overall objective of the AMR is to strengthen the effectiveness of regulatory systems and to provide the FDA and the relevant authorities of EU Member States with a more practical way of supervising the large number of establishments that manufacture veterinary medicines at these sites. Using inspection reports and related information, an FDA and EU MRA can ultimately enable the FDA and EU to avoid double checks during certain veterinary drug inspections and allow regulators to devote more resources to other areas that may be more at risk. The secretariat for economic affairs may enter into mutual recognition agreements for the results of the compliance assessment with international and foreign institutions, which are implemented by accredited agencies and individuals. The agreements must be in line with the provisions of international treaties signed by Mexico. Mutual recognition agreements (MRAs) promote trade in goods between the European Union and third countries and facilitate market access. These are bilateral agreements designed to facilitate industry access to compliance assessment. Mutual recognition agreements set out the conditions under which a party (non-member state) accepts compliance assessment results (for example.

B tests or certifications) conducted by the compliance assessment agencies (CABs) designated by the other party to demonstrate compliance with the requirements of the first part (non-member) and vice versa. The text of the Protocol on Mutual Recognition of the Results of the Compliance Assessment is part of the Comprehensive Economic and Trade Agreement (CETA) between Canada on the one hand and the European Union and its Member States on the other. . The U.S. Food and Drug Administration announced that the FDA Center for Veterinary Medicine (CVM) of the European Union (EU) and the Commission (EC) have notified the decision of the Joint Sectoral COMITÉ of December 2019 regarding the decision of the CVM to include veterinary drugs under the FDA/EU Agreement on the Recognition of Veterinary Drugs (MRA) for good quality pharmaceutical inspections. The EU has also agreed on the principle of the inclusion of veterinary medicines in the AMR.